FDA data link hydroxychloroquine and chloroquine to severe cardiovascular side effects
Hydroxychloroquine and chloroquine, two antimalarial drugs repeatedly discussed as potential COVID-19 treatments, are associated with high rates of cardiovascular adverse events (CVAEs), according to new findings published in the British Journal of Clinical Pharmacology. The authors studied more than 6.6 million reports from the FDA’s Adverse…